These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 12384539)

  • 41. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
    Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
    Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
    Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
    Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of secondary antigen-specific CD8(+) T-cell responses by natural killer T cells.
    Hong C; Lee H; Park YK; Shin J; Jung S; Kim H; Hong S; Park SH
    Cancer Res; 2009 May; 69(10):4301-8. PubMed ID: 19401453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD8+ T cells mediate aortic allograft vasculopathy by direct killing and an interferon-gamma-dependent indirect pathway.
    Skaro AI; Liwski RS; Zhou J; Vessie EL; Lee TD; Hirsch GM
    Cardiovasc Res; 2005 Jan; 65(1):283-91. PubMed ID: 15621057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients.
    Wang H; Yang D; Xu W; Wang Y; Ruan Z; Zhao T; Han J; Wu Y
    Immunol Lett; 2008 Oct; 120(1-2):65-71. PubMed ID: 18672004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NK cells promote islet allograft tolerance via a perforin-dependent mechanism.
    Beilke JN; Kuhl NR; Van Kaer L; Gill RG
    Nat Med; 2005 Oct; 11(10):1059-65. PubMed ID: 16155578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
    Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
    Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
    Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
    Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behçet uveitis.
    Ahn JK; Park YG; Park SW; Yoon KC; Yu HG; Chung H
    Ocul Immunol Inflamm; 2006 Oct; 14(5):267-75. PubMed ID: 17056460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
    Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
    Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
    J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Bi-specific F(ab')2 enhances cytolytic activities of LAK cells against human small cell lung cancer (SCLC)].
    Azuma A; Niitani H
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1132-7. PubMed ID: 1661346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells.
    Sconocchia G; Titus JA; Segal DM
    J Immunol; 1994 Dec; 153(12):5473-81. PubMed ID: 7527443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
    Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
    J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
    J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.